News & Updates

Uncontrolled diabetes among older adults with preclinical heart failure (HF) stages appears to increase the risk of HF progression, suggests a study.

The risks of cardiovascular disease (CVD) and end-stage kidney disease (ESKD) are elevated twofold in individuals with youth-onset type 2 diabetes (T2D), which is partly caused by the greater burden of obesity and other metabolic risk factors in this population, relative to those with type 1 diabetes (T1D), according to a Hong Kong study.

A new study presented at the recent 2022 Scientific Sessions of the American Diabetes Association (ADA 2022) has identified a novel genetic locus associated with heart failure (HF) risk among patients with type 2 diabetes (T2D). This locus appears to play a role in the metabolism of valine, a branched chain amino acid.

Use of an antihypertensive drug does not appear to reduce the risk of all-cause mortality or hospital readmission in hospitalized older patients with heart failure with reduced ejection fraction (HFrEF) who are receiving contemporary treatments for HF, reveals a recent study.

In addition to cardiometabolic benefits, a lifestyle intervention aimed at weight loss in patients with chronic obstructive pulmonary disease (COPD) who are overweight or obese may reduce COPD symptoms, according to results of the INSIGHT COPD trial presented at ATS 2022.

Men receiving testosterone therapy (TT) who develop polycythemia are at greater risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year of therapy, according to a recent study.

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).